Home›Stock Screener›Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Share Price Today | Stock Price & Glenmark Pharmaceuticals Share Screener

GLENMARK Pharmaceuticals & Biotechnology
Live Share Price NSE
₹2646.10
▲ 30.30 (1.16%)
2026-11-18 00:00:00
Live Share Price BSE
₹2655.00
▲ 41.20 (1.58%)
2026-11-18 00:00:00

As of November 18, 2026, the live Glenmark Pharmaceuticals share price (NSE: GLENMARK) is ₹2,646.10 on NSE and ₹2,655.00 on BSE, up 1.16% from the previous close, with shares trading between ₹2,625.10 and ₹2,691.50 in today's trading session, and a 52-week range of ₹1,842.40–₹2,677.20. Track Glenmark Pharmaceuticals market cap to gauge the company's total market size. Use the Glenmark Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Glenmark Pharmaceuticals opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹3,949 and net income of ₹301, with EBITDA of ₹568, an operating margin of 10.0% and a profit margin of 7.6%.

Glenmark Pharmaceuticals Market Cap ₹74,306.93 Cr.
GLENMARK P/E Ratio (TTM) 51.40
Glenmark Pharmaceuticals P/B Ratio 6.65
EPS (TTM) ₹48.26
Dividend Yield 0.19%
Debt to Equity 0.16
GLENMARK 52 Week High ₹2677.20
Glenmark Pharmaceuticals 52 Week Low ₹1842.40
Operating Margin 10.00%
Profit Margin 7.62%
GLENMARK Revenue (TTM) ₹3,949.00
EBITDA ₹568.00
Net Income ₹301.00
Total Assets ₹19,908.00
Total Equity ₹10,512.00

Glenmark Pharmaceuticals Share Price Chart

Track the current stock price of Glenmark Pharmaceuticals with an interactive chart. Analyse GLENMARK share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Glenmark Pharmaceuticals stock quote in one place.

The quote of ₹2,646.10 sits between the 52-week low of ₹1,842.40 and the 52-week high of ₹2,677.20, and the latest session moved 1.16% from the previous close.

Glenmark Pharmaceuticals Company Profile - Fundamental Screener

Screen Glenmark Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for GLENMARK shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, with Glenn Saldanha listed as chairperson or CEO, and it trades under ISIN INE935A01035.

Business Overview

Glenmark Pharmaceuticals Ltd is an Indian research-led global pharmaceutical company founded in 1977. It focuses on developing and manufacturing branded generics, generic drugs, and over-the-counter products in therapeutic areas like respiratory, dermatology, and oncology. The company has a significant presence in emerging markets and operates 14 manufacturing facilities across several...more

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

Chairperson/CEO Glenn Saldanha
ISIN INE935A01035

Glenmark Pharmaceuticals Balance Sheet Screener

Screen GLENMARK balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹19,908, up from ₹16,050 in 2025.

Latest statistics put total assets at ₹19,908 and shareholder funds at ₹10,512, with a leverage ratio of 0.16.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 19,908 16,050 14,359 19,372 17,083 15,604 14,685 13,289 12,595 11,764
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 5,915 4,487 4,210 5,422 5,887 5,129 5,029 3,670 3,030 2,755

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 3,020 1,234 693 4,427 2,956 4,338 4,489 3,663 4,144 4,569
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 10,512 8,849 7,848 9,839 9,438 7,064 6,070 5,605 5,163 4,492
Share Capital 28 28 28 28 28 28 28 28 28 28
Reserves & Surplus 10,484 8,821 7,820 9,446 9,058 7,036 6,042 5,577 5,135 4,464

Glenmark Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis

Screen Glenmark Pharmaceuticals income statement and profit fundamentals. Analyze GLENMARK quarterly results. Glenmark Pharmaceuticals reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Mar, revenue was ₹3,949 and net profit was ₹301, equal to earnings per unit of ₹10.68, at an operating margin of 10%.

In that period expenses were ₹3,381, interest cost ₹43 and tax ₹86. The next period listed, 2026-Jun, shows revenue of ₹3,998 and net profit of ₹483.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec

Revenue and Expenses

Revenue 3,949 3,998 4,160 3,232 3,086 6,204 3,933 3,814 3,255 3,440 3,333 3,062 3,018 3,281 2,625
Expenses 3,381 3,214 3,667 3,068 3,007 5,072 3,215 3,005 2,656 2,832 2,787 3,402 2,651 3,071 2,792

Operating Costs and Margins

EBITDA 568 784 492 164 79 1,132 717 808 599 608 546 -340 367 211 -168
Operating Profit % 10.00% 18.00% 12.00% 5.00% 2.00% 16.00% 17.00% 0.00% 18.00% 17.00% 16.00% -15.00% 12.00% 3.00% -13.00%
Depreciation 148 173 180 125 130 141 154 151 118 120 123 135 142 141 147
Interest 43 54 64 67 58 67 41 149 40 49 52 109 112 122 134

Profit and Earnings

Profit Before Tax 388 643 338 8 96 967 534 555 462 473 456 -542 151 -6 -403
Tax 86 161 75 4 49 357 131 1,770 122 118 108 -139 -22 56 -72
Net Profit 301 483 264 4 47 610 403 -1,214 340 355 348 -403 173 -62 -331
EPS 10.68 17.11 9.35 0.16 1.66 21.63 14.29 -43.17 12.06 12.55 12.33 -15.18 5.31 -2.90 -12.45

Glenmark Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals

Screen GLENMARK cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹3,445, and net cash flow was an outflow of ₹501.

Over the same period, investing activities used ₹1,237 and financing activities used ₹2,709.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 3,445 -828 -265 625 1,109 1,131 1,392 1,324 1,648 657
Investing Activities -1,237 58 4,387 -515 -316 -662 -774 -883 -1,003 -1,001

Financing and Net Cash

Financing Activities -2,709 787 -3,906 -78 -521 -442 -445 -739 -469 543
Net Cash Flow -501 17 215 33 272 28 174 -297 177 199

Glenmark Pharmaceuticals Shareholding Pattern Screener

See Glenmark Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings. Check Glenmark Pharmaceuticals promoter holding and ownership changes for GLENMARK on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Sept, promoters held 46.65%, foreign institutions 21.51%, domestic institutions 17.64% and the public 10.44%, spread across 208,414 shareholders.

The shareholder count was 208,414 in 2026-Sept, compared with 211,418 in 2026-Jun.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec

Promoter Holding

Promoter Holding 46.65% 46.65% 46.65% 46.65% 46.65% 46.65% 46.65% 46.65%

Institutional Investors

FII Holding 21.51% 20.89% 20.34% 19.20% 20.73% 20.62% 23.16% 23.51%
DII Holding 17.64% 18.60% 19.29% 20.09% 18.61% 17.64% 14.60% 13.85%

Government, Public and Others

Govt Holding 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04%
Public Holding 10.44% 10.60% 10.32% 10.77% 10.81% 11.69% 12.32% 12.65%
Other Holding 3.73% 3.21% 3.36% 3.26% 3.16% 3.37% 3.24% 3.31%
Shareholder Count 208,414 211,418 196,105 201,584 198,789 190,210 192,724 195,059

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Glenmark Pharmaceuticals. Glenmark Pharmaceuticals dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹5.00 per unit for 2026-March, a yield of 0.19%, compared with ₹2.50 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹5.00, ₹2.50 and ₹2.50 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹5.00 0.19%
2025-March ₹2.50 0.12%
2024-March ₹2.50 0.16%
2023-March ₹2.50 0.26%
2022-March ₹2.50 0.56%
2021-March ₹2.50 0.57%
2020-March ₹2.50 0.54%
2019-March ₹2.00 0.97%
2018-March ₹2.00 0.31%
2017-March ₹2.00 0.38%

Glenmark Pharmaceuticals Stock Index Membership - Nifty & Sensex

See which indices include Glenmark Pharmaceuticals stock. Check GLENMARK index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 28 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX BSE500, BSE INDEX BSEMOI.

Complete Index List

BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX BSEMOI
BSE INDEX LMI250
BSE INDEX MID150
BSE INDEX MIDCAP
BSE INDEX MSL400
NIFTY 200
NIFTY 500
NIFTY ALPHA 50
NIFTY HEALTHCARE
NIFTY LARGEMID250
NIFTY MIDCAP 100
NIFTY MIDCAP 150
NIFTY MIDSMALLCAP400 MOMENTUM QUALITY 100
NIFTY MIDSML 400
NIFTY MIDSML HLTH
NIFTY MULTI MFG
NIFTY PHARMA
NIFTY SMALLCAP250 MOMENTUM QUALITY 100
NIFTY TOTAL MKT
NIFTY200 ALPHA 30
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MOMENTUM 50
NIFTY500 MULTICAP
NIFTY500 SHARIAH

Glenmark Pharmaceuticals Market Events Screener - Corporate Actions

Get Glenmark Pharmaceuticals corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Glenmark Pharmaceuticals stock events that may affect GLENMARK share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 5, 2026, with a record date of November 5, 2026.

It is followed by Annual General Meeting dated September 11, 2026 and Dividend dated August 31, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-05 2026-11-05 Quarterly Result Announcement NA 14.73%
2026-09-11 2026-09-11 Annual General Meeting NA 10.26%
2026-08-31 2026-08-31 Dividend ₹ 2.50 /share 5.56%
2026-07-31 2026-07-31 Quarterly Result Announcement NA -4.98%
2026-05-29 2026-05-29 Quarterly Result Announcement NA 1.90%
2026-01-30 2026-01-30 Quarterly Result Announcement NA -0.69%
2025-11-14 2025-11-14 Quarterly Result Announcement NA -0.74%
2025-10-03 2025-10-03 Dividend ₹ 2.50 /share -3.56%
2025-09-26 2025-09-26 Annual General Meeting NA 4.61%
2025-09-15 2025-09-15 Dividend ₹ 2.50 /share 49.01%
2025-08-14 2025-08-14 Quarterly Result Announcement NA -1.86%
2025-05-23 2025-05-23 Quarterly Result Announcement NA 2.35%
2025-02-14 2025-02-14 Quarterly Result Announcement NA -1.75%
2024-11-14 2024-11-14 Quarterly Result Announcement NA -8.04%
2024-09-27 2024-09-27 Annual General Meeting NA -0.47%

Glenmark Pharmaceuticals Competitors Screener - Peer Stocks Comparison

Screen GLENMARK competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 448,076 41.10 61,674 12.69% 11,565 59.98
Divis Laboratories 294,139 90.70 11,067 13.95% 2,568 67.88
Torrent Pharmaceuticals 178,438 84.50 13,886 20.34% 2,138 49.31
Laurus Labs 119,949 98.10 6,868 22.01% 890 49.19
Zydus Life Science 118,902 27.60 27,658 17.64% 5,026 52.87
Dr Reddys Laboratories 115,011 41.70 35,059 3.90% 4,158 69.34
Cipla 112,656 39.40 29,045 2.24% 3,870 55.82
Mankind Pharma 108,490 48.40 14,636 14.85% 1,938 63.62
Aurobindo Pharma 103,223 26.40 34,145 5.56% 3,503 60.38
Lupin 90,393 17.30 29,039 26.75% 5,356 44.23

Glenmark Pharmaceuticals Company Announcements - News & Reports Screener

Screen GLENMARK latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated .

The next most recent announcements are dated November 14, 2026 and November 14, 2026.

Date Update Actions
Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-11-14 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-11-14 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-11-14 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-11-13 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-11-13 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-11-10 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-11-10 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-11-05 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-11-05 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-11-05 Results-Financial Results For September 30 2026 -
2026-11-04 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-10-23 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-23 Board Meeting Intimation for To Consider And Approve The Unaudited Financial Results Of Glenmark Pharmaceuticals Limited (The Company) For The Quarter And Half Year Ended September 30 2026 -
2026-10-06 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-09-28 Closure of Trading Window -
2026-09-23 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-09-21 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-09-11 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-11 Shareholder Meeting / Postal Ballot-Outcome of AGM -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹2,646.10, within a 52-week range of ₹1,842.40 to ₹2,677.20. The P/E ratio is 51.40 and the P/B ratio is 6.65, with earnings per unit of ₹48.26. Market capitalisation stands at ₹74,306.93 Cr and the dividend yield is 0.19%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.